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Important antibody-independent pathogenic roles of B cells are emerging in autoim-
mune diseases, including multiple sclerosis (MS). The contrasting results of different 
treatments targeting B cells in patients (in spite of predictions of therapeutic benefits 
from animal models) call for a better understanding of the multiple roles that distinct 
human B cell responses likely play in MS. In recent years, both murine and human B 
cells have been identified with distinct functional properties related to their expression of 
particular cytokines. These have included regulatory (Breg) B cells (secreting interleukin 
(IL)-10 or IL-35) and pro-inflammatory B cells (secreting tumor necrosis factor α, LTα, 
IL-6, and granulocyte macrophage colony-stimulating factor). Better understanding of 
human cytokine-defined B cell responses is necessary in both health and diseases, such 
as MS. Investigation of their surface phenotype, distinct functions, and the mechanisms 
of regulation (both cell intrinsic and cell extrinsic) may help develop effective treatments 
that are more selective and safe. In this review, we focus on mechanisms by which cyto-
kine-defined B cells contribute to the peripheral immune cascades that are thought to 
underlie MS relapses, and the impact of B cell-directed therapies on these mechanisms.
Keywords: multiple sclerosis, B-lymphocytes, cytokine-defined responses, immune modulation, B-cell depletion, 
B cell modulation
inTRODUCTiOn
In addition to their potential to differentiate into antibody producing plasma cells, B cells can effi-
ciently present antigens to T cells and modulate local immune responses through secretion of soluble 
products, such as pro-inflammatory or anti-inflammatory cytokines (Figure  1) (1). Historically, 
B-cell implication in multiple sclerosis (MS) pathogenesis was based on the common finding of 
abnormally increased immunoglobulin levels in the cerebrospinal fluid (CSF) of patients as well as 
antibody deposition noted in brain lesions (2–5). However, the success of B-cell-depleting therapy 
to limit new MS relapses without obviously impacting abnormal CSF antibody levels underscores 
antibody-independent contributions of B cells to relapsing disease activity (6–11). In this review, we 
focus on implication of pro-inflammatory or anti-inflammatory cytokine-defined B cell responses 
in MS and the impact of B-cell-directed therapies on their functions.
FiGURe 1 | Multifaceted functions of B cells and their implications in the pathogenesis of MS. In addition to their potential to differentiate into antibody-
secreting plasmablasts and plasma cells, B cells can present antigen to T cells, as well as up- or down-regulate local immune responses through elaboration of 
pro- or anti-inflammatory cytokine, respectively. Plasma cells can also secrete pro- and anti-inflammatory cytokines that could modulate T cell and myeloid-cell 
responses. Abnormal B cell responses of potential relevance to MS include aberrant production of autoreactive antibodies, exaggerated activation of T cells through 
antigen presentation, and induction of pro-inflammatory T cell and myeloid-cell responses through abnormal secretion of pro-inflammatory B cell cytokines and/or 
insufficient secretion of B cell regulatory cytokines.
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CYTOKine-DeFineD B CeLL ReSPOnSeS 
in MS AnD eAe
Several functionally distinct cytokine-defined B cell responses have 
been implicated in the pathophysiology of MS and its commonly 
used animal model, experimental autoimmune encephalomy-
elitis (EAE). Nonetheless, translation of B-cell-related findings 
from mouse to human has not always been straightforward. 
Characterizing and defining the roles of distinct human B cell 
subsets in health and disease are important requisites for rational 
development of more selective and effective B cell-targeting 
therapies.
inTeRLeUKin-10-PRODUCinG B CeLLS
Interleukin (IL)-10 is a cytokine with pleiotropic effects in 
immunoregulation and inflammation (12). In mice, knock-out 
(KO) of IL-10 selectively from B cells results in more severe EAE 
(13), and adoptive transfer of in vitro-induced IL-10-producing 
B cells suppresses EAE in an IL-10-dependent manner (14–16). 
Inducing EAE in IL-10 reporter mice implicated the draining 
lymph nodes (rather than spleen or spinal cord) as the sites 
where IL-10+ B cells regulate disease-relevant immune responses 
(17). The IL-10+ B cells in this study exhibited plasma cell/
plasmablast markers, consistent with an earlier report showing 
that CD138+ plasma cells are able to produce IL-10 (17), thus 
also highlighting the previously unappreciated antibody-inde-
pendent functions of plasma cells. Although IL-10 production 
from B cells can be induced by both innate [toll-like receptors 
(TLRs)] and adaptive (cognate interaction) stimuli (14, 16, 
18), the targets of regulation of innate- and adaptive-induced 
IL-10-producing B cells may differ depending on context. For 
example, innate signal-induced IL-10-producing B cells are 
able to down-regulate pathogenic T-cell responses indirectly 
through dendritic cells (14), whereas adaptive signal-induced 
IL-10-producing B cells directly down-regulate antigen-specific 
T-cell responses (15, 16).
In humans, both naïve and memory B cells are capable of 
producing IL-10 in a context-dependent manner (19–22). 
Human CD27− (naïve) B cells, but not CD27+ (memory) B cells, 
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are able to produce IL-10 upon CD40-ligand stimulation (11, 
23–25), a response found to be abnormally deficient in B cells 
of MS patients (24). By contrast, IL-10+ B10 cells are induced 
within the CD27+ memory pool by stimulation through TLR4 
and TLR9 and can suppress tumor necrosis factor α (TNFα) pro-
duction by monocytes through an IL-10-dependent mechanism. 
Unexpectedly, B10 cells were reportedly increased in several 
human autoimmune diseases, including MS, upon stimulation 
(21). A better understanding of these cells, including defining 
surface markers and master transcriptional regulators, could 
facilitate future cell-based therapies for MS.
iL-35 PRODUCinG B CeLLS
Interleukin-35 is an anti-inflammatory cytokine of the IL-12 
family (26). Although the EBI3 subunit of IL-35 was first 
identified in EBV-infected B cells (27), functions of IL-35 were 
initially described in regulatory T cells (28–30). More recently, 
IL-35-producing B cells were found to play important roles in 
recovery from EAE and experimental autoimmune uveitis (31, 
32). In these contexts, IL-35-producing B cells inhibited pro-
inflammatory immune responses either directly through IL-35 
(31) or indirectly through induction of IL-10-producing B cells 
(32). These IL-35-producing B cells also exhibited plasma cell 
phenotypic markers (31). Besides IL-10 and IL-35, B cells can 
also produce Transforming-growth factor β or Granzyme B that 
may down-regulate immune responses (33–39); their relevance 
to MS (or EAE) is yet to be determined.
TUMOR neCROSiS FACTOR α AnD 
LYMPHOTOXin-α PRODUCinG B CeLLS
Tumor necrosis factor α and Lymphotoxin-α (LTα) are actively 
involved in promoting pro-inflammatory immune responses to 
protect against pathogen invasion (40). In addition, TNFα is also 
known to play a pathogenic role in several autoimmune diseases, 
including rheumatoid arthritis (41) and inflammatory bowel 
disease (42), in which TNFα-blocking therapies have been suc-
cessful (41). In MS, however, TNFα blockade increased disease 
activity (43) highlighting the challenge of broadly targeting indi-
vidual cytokines (versus targeting particular cytokine-expressing 
cells). Stimulation through CD40 and the B-cell receptor (BCR) 
significantly increases TNFα and LTα secretion from human B 
cells, compared to either stimulation alone (19). B cells of MS 
patients produce abnormally higher levels of both TNFα and LTα 
upon such dual stimulation (11, 23, 24). A microRNA (miR)-
132:SIRT1 axis controls expression of TNFα and LTα by human 
B cells (23). Abnormally increased expression of miR-132 by MS 
B cells inhibited their SIRT1 expression, resulting in enhanced 
pro-inflammatory cytokine production. In  vitro addition of 
the SIRT1-agonist resveratrol normalized the exaggerated pro-
inflammatory cytokine expression of MS B cells (23).
iL-6 PRODUCinG B CeLLS
Interleukin-6, a cytokine with both pro-inflammatory and anti-
inflammatory properties, can be produced by both immune and 
non-immune cells (44). IL-6 can induce Th17-cell differentiation 
from naïve T cells (45) and inhibit regulatory T cells (46–48). By 
contrast, IL-6 may induce IL-10-producing regulatory B cells and 
myeloid cells (18, 49). B cells of MS patients secrete abnormally 
high levels of IL-6 (50) and IL-6 knock-out selectively from B cells 
resulted in decreased Th17 responses and diminished EAE sever-
ity (50, 51). How B cell-derived IL-6 is regulated, and whether 
B-cell IL-6 also contributes to Th17 differentiation and regulatory 
T-cell dysfunction in MS, remains unknown.
iL-15 PRODUCinG B CeLLS
Interleukin-15 belongs to the four α-helix bundle family of 
cytokines and can be produced by multiple cell types (52). 
IL-15 knock-out mice develop more severe EAE (53), in part 
attributed to IL-15’s ability to inhibit pathogenic Th17-cell 
differentiation (54), and to induce regulatory CD8+ CD122+ T 
cells (55). In patients with MS, however, IL-15 is abnormally 
increased in both serum and CSF (56, 57), where it may have 
disease-promoting (rather than disease-inhibiting) potential 
(58, 59). B cells from MS patients reportedly produce more 
IL-15 than controls, and activation of B cells through CD40 
and the BCR induces IL-15 secretion that enhanced both 
the migratory capacity of CD8+ T cells across a model of 
the blood–brain barrier and CD8+ T cell cytotoxicity toward 
oligodentrocytes (59).
GRAnULOCYTe MACROPHAGe COLOnY-
STiMULATinG FACTOR-PRODUCinG B 
CeLLS
Granulocyte macrophage colony-stimulating factor (GM-CSF) 
is an important growth factor for myeloid lineage cell develop-
ment and function, which is secreted by both immune and 
non-immune cells during infection and autoimmune disease 
(60). GM-CSF KO is resistant to active EAE induction (61), 
and GM-CSF KO Th17 cells fail to induce passive EAE (62–64). 
Since GM-CSF-producing T cells are reportedly increased in the 
circulation of MS patients (65–67), T cells have been thought 
to be the main source of GM-CSF of relevance to MS and EAE 
(65–68). A murine B-cell population generated from B1a cells, 
termed “innate response activator (IRA)” B cells (69), was 
described to produce GM-CSF and found to play a GM-CSF-
mediated protective role during infections (69, 70), as well as 
a GM-CSF-mediated pathogenic role in atherosclerosis (71). In 
contrast to the murine IRA cells, a recently described human 
GM-CSF producing B cell subset belonged to the memory 
pool, and co-expressed high levels of TNFα and IL-6 (72). 
The human GM-CSF-producing B cells enhanced myeloid-cell 
pro-inflammatory responses in a GM-CSF-dependent manner 
and were abnormally increased in MS patients. B cell depletion 
in patients with MS resulted in a B cell–GM-CSF-dependent 
decrease of pro-inflammatory myeloid-cell responses, high-
lighting the potential pathogenic role of this B cell population 
in vivo and revealing a novel disease-implicated axis involving B 
cell:myeloid-cell interactions (72).
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B CeLL-TARGeTinG THeRAPieS AnD 
eFFeCTS in MS
The use of B cell-depleting agents in MS was initially driven by 
the long-standing recognition of abnormal antibody presence in 
both the CSF and brain lesions of MS patients (2–4, 73). Therapies 
directed against B cells include agents that impact their survival 
(rituximab, ocrelizumab, ofatumumab, alemtuzumab, and 
atacicept), and their trafficking to the CNS (natalizumab and 
fingolimod). In this section, we will highlight the mechanisms of 
action of these and other MS-related therapies that may impact 
B cells, with a focus on how such therapies may influence MS 
disease-relevant cytokine-defined B cells responses.
AnTi-CD20 MOnOCLOnAL AnTiBODieS
CD20 is a transmembrane protein with incompletely understood 
function, expressed on immature, transitional, naïve, and memory 
B cells, but not on stem cells, pro-B cells, and plasma cells (74). 
Rituximab, ocrelizumab, and ofatumumab are anti-CD20 mono-
clonal antibodies that induce B cell lysis via different combinations 
of antibody-dependent cell cytotoxicity, complement-dependent 
cytotoxicity, or apoptosis (75, 76). In MS, anti-CD20 antibodies 
rapidly and significantly reduced the number of new gadolinium-
enhancing brain lesions and significantly reduced relapse rates 
(6–10, 77). Treatment reduced circulating B cell counts by >90% 
of baseline values, while serum and CSF immunoglobulin G levels 
remained largely unchanged (77–79), pointing to an important 
antibody-independent contribution of B cells to MS relapsing 
disease activity. An attractive hypothesis that has emerged is that 
pro-inflammatory B cells in untreated patients abnormally acti-
vate disease-relevant responses of other immune cells  –  hence 
removal of such B cells diminishes disease activity. In support of 
this view, anti-CD20-mediated B-cell depletion decreases both 
Th1 and Th17 T cell responses (11, 50) and pro-inflammatory 
myeloid-cell responses (that in turn could drive Th1 and Th17 
responses) in the periphery of treated patients (72). In addition 
to cognate interactions in which B cells may serve as efficient 
antigen-presenting cells (APC) to activate T cells that recognize 
the same antigen, abnormal B-cell secretion of pro-inflammatory 
cytokines (including IL-6, TNFα, LTα, and GM-CSF) has now 
been implicated in abnormal T-cell and myeloid-cell responses of 
MS patients and may involve “bystander activation” (i.e., not be 
predicated by cognate antigen-specific interactions). Rituximab 
treatment could also diminish T cells within the CSF (79), pro-
viding further support that, when present, B cells may contribute 
to disease activity by enhancing peripheral T-cell activation and 
trafficking, and/or by CNS resident B cells promoting chemotaxis 
of T cells into the CNS. Alternative mechanisms proposed include 
an increased frequency of circulating regulatory T cells following 
B cell depletion (80) and in addition to depleting circulating B 
cells, anti-CD20 treatment also removes a small population of 
CD20dim T cells (81, 82). Initial studies of this T cell subset point 
to their potential to produce pro-inflammatory cytokines (81), 
though their significance in relation to MS disease activity war-
rants further investigation.
Elegant work using somatic mutation analysis of the Ig gene in 
B cells derived from both CNS and peripheral compartments of 
the same MS patients indicates that bi-directional trafficking of B 
cells occurs between the CNS and periphery and that much of the 
activation and maturation that results in clonal enrichment of B 
cells within the CNS may actually occur in the periphery (presum-
ably through cognate–antigen interactions with T cells) (83–86). 
Hence, efforts to deplete or modulate the profile and functions of 
B cells in peripheral compartments of MS patients may meaning-
fully influence the profile and activities of B cells within the CNS, 
even if the treatment itself does not efficiently penetrate the CNS 
(as is generally the case for monoclonal antibodies). There have 
also been efforts to selectively eliminate B cells in the CNS using 
intrathecally administered rituximab (87). However, a complica-
tion in interpreting this result has been the finding that even 
small doses of rituximab infused into the CSF results in rapid and 
substantial peripheral B cell depletion (87). Data regarding effects 
of anti-CD20-mediated peripheral B-cell depletion on inflamma-
tion within the CNS compartment remain limited. Early work 
suggested that rituximab may be more effective at depleting CSF 
B cells in patients with relapsing compared to progressive forms 
of MS (77, 78), possibly due to differences in Blood-brain barrier 
permeability. In the earlier OLYMPUS trial (88), rituximab failed 
to limit progression of disability in PPMS patients compared 
to placebo treatment, though post  hoc sub-group analysis sug-
gested that patients who had gadolinium-enhancing lesions at 
baseline, and particularly younger patients, did benefit (88). The 
ORATORIO study, focusing on earlier disease, and using ocreli-
zumab, demonstrated that anti-CD20 therapy could limit disease 
progression in PPMS patients (89). The mechanisms underlying 
this benefit of B cell depletion in patients with progressive MS 
remain to be elucidated (see Michel et al., in this issue).
In addition to the decreased MS disease activity observed 
following B cell depletion with anti-CD20 antibodies, there is a 
suggestion that the benefit of B cell depletion may persist in at 
least some patients even as reconstitution of B cells occurs (6, 7). 
This would imply that the re-emerging B cells differ importantly 
from the B cells present prior to depletion. Indeed, the B cells that 
reconstitute following anti-CD20 depletion have been shown to 
be largely naïve B cells which, when activated, express more IL-10 
and less pro-inflammatory cytokines, including TNFα, IL-6, and 
GM-CSF, compared to pre-treatment B cells (72).
ATACiCePT
B-cell activating factor of the TNF family (BAFF) and a prolif-
eration-inducing ligand (APRIL) are expressed by a variety of 
immune and non-immune cells (90, 91). Both cytokines signal 
through transmembrane activator and cyclophilin ligand inter-
actor (TACI) and B cell maturation antigen (BCMA), while only 
BAFF binds to BAFF-R (90, 91). Both play important roles in 
the survival, maturation, and function of B cells and plasma cells 
(92–94). BAFF can also promote differentiation and expansion 
of Th17 cells in models of infectious and autoimmune diseases 
(95). BAFF and APRIL levels are reportedly elevated in MS 
patients (96, 97), where they are highly expressed by peripheral 
blood monocytes and T cells. BAFF is also abnormally expressed 
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by astrocytes within MS lesions (77–79, 98). Atacicept, a soluble, 
recombinant fusion protein containing the extracellular ligand-
binding portion of TACI receptor and a modified Fc portion 
of human IgG, prevents binding of BAFF and APRIL to their 
receptors (99). Atacicept thereby limits survival of mature and 
activated B cells as well as antibody-secreting plasma cells but 
does not appear to target pro- or memory B cells (100, 101). 
Treatment with atacicept reduces circulating B cell counts (by 
60–70%) and substantially reduces serum IgM and IgA (but 
to a lesser extent IgG) levels (100, 102–104). While emerging 
as beneficial in systemic lupus erythematosus, development of 
atacicept in MS was halted due to increased relapsing disease 
activity (100, 103–105). Why atacicept induced rather than lim-
ited new MS disease activity remains unknown but may reflect 
differential effects on functionally distinct B cell or plasma cell 
responses. Indeed, BAFF can induce IL-10-producing B cells 
and suppress the generation of IL-15+ B cells (106). Hence, the 
dysregulated cytokine balance in B cells of untreated MS patients 
may actually be aggravated by atacicept, leading to aberrant 
responses of disease-relevant immune cells, such as pathogenic 
T cells and myeloid cells.
APPROveD MS THeRAPieS THAT MAY 
iMPACT B CeLL ReSPOnSeS
While most approved MS therapies were developed based on 
their presumed ability to target T cells, many of them are now 
understood to also impact B cells in potentially disease-relevant 
ways (Table  1). For example, interferon (IFN)-β decreases the 
frequency of CD80-expressing B cells in treated MS patients, 
which could in turn limit peripheral T cell activation (107). 
IFN-β also enhances the numbers of circulating transitional B 
cells (108) and, such as glatiramer acetate (GA), may result in an 
TABLe 1 | Selected therapies approved for (or under investigation for) multiple sclerosis, and their in vivo effects on the profiles and cytokine responses 
of B cells.
Drug name Main drug target(s) effects on peripheral B cell subsets Changes in expression of B cell 
cytokines
IFN-β IFN-βR ⇑ CD19+ B cells (108) ⇑ IL-10, TGF-β, IL-12p70, IL-27p28 (108, 
109)
⇑ CD19+CD24++CD38++ B cells (108) ⇓ IL-1β, IL-23p19/40 (108, 109)
⇓ % CD19+CD38−IgM−IgD− (108)
⇓ % CD80+ B cells (107, 109)
⇓ % CD40+ B cells (109)
Glatiramer acetate MHC class II (126) ⇓ CD19+ B cells (127) ⇑ IL-10, IL-6 (127)
⇓ % CD27− B cells (128) ⇓ LTα (127)
Natalizumab Alpha-4-integrin ⇑ % CD19+ B cells (114–116, 129) Unknown
⇑ CD19+CD10−CD138− B cells (130)
⇑ CD19+CD10+ pre-B cells (130)
⇑ % CD27+IgD+ B cells (114)
⇓% CD27−IgD+ B cells (114)
⇑ % CD27+IgD− B cells (114)
Mitoxantrone Type II topoisomerase (121, 131) ⇓ CD19+ B cells (132) ⇑ IL-10 (24)
⇓ % CD27+ B cells (24) ⇓ LTα (24)
Fingolimod S1P1R ⇓ CD19+ B cells (116–119) ⇑ IL-10, ⇓TNFα (117, 120)
⇓ % CD27+ CD38int-low B cells (117, 120)
⇑ % CD27− B cells (117, 119, 120)
⇑ % CD38+CD27−CD24+CD5+ B cells (120)
⇑ % CD10+CD38hiCD24hi B cells (117)
Dimethyl-fumarate Nrf2 (133) ⇓ CD19+ B cells (124, 125) Unknown
Teriflunomide Mitonchondrial enzyme dihydroorotate 
dehydrogenase (DHODH) (134)
⇓ Proliferation of T cells and B cells Unknown
⇓ Antibody titers against neoantigen but not recall 
antigens (135, 136)
Alemtuzumab CD52 ⇓ CD19+ B cells (123, 137, 138) May result in shift in the balance between 
pro- and anti-inflammatory cytokine 
networks in B cells
⇑ CD19+CD23−CD27– (after 1 month) (137)
⇑ CD19+CD23+CD27− (after 3–12 months) (137)
Partial reconstitution of CD19+CD23+CD27+ B cells 
(after 12 month) (137)
⇑ CD19+CD24hiCD38hi (at 6 months) (123)
Rituximab CD20 ⇓ CD19+ B cells (but not plasma cells) ⇓ IL-6, TNFα, LTα
Ocrelizumab
Ofatumumab
Early reconstitution of CD27−B cells and 
CD19+IgD+CD38hiCD10loCD24hi B cells (6–10, 79, 98)
⇓ GM-CSF
⇑ IL-10 (11, 24, 50)
Daclizumab IL-2R-α ⇓ CD19+ B cells (139) Unknown
No change in CD19+ B cells (140)
Atacicepta BAFF/APRIL ⇓ % mature B cells and plasma cells (not memory B 
cells) (101, 103, 105)
Unknown but may result in ⇓ IL-10 and 
IL-35
aClinical trial program of atacicept in MS was discontinued when early studies indicated treatment resulted in increased disease activity (103).
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anti-inflammatory shift of B cell cytokine responses (109, 110). 
Both treatment with IFN-β and GA unexpectedly increased serum 
BAFF (111, 112), which would not only support certain aspects of 
B cells and plasma cells but may also shape the balance between 
cytokine-defined B cells, as described above. While natalizumab 
modifies frequencies of circulating B cells and plasma cells 
(Table 1) its effects, if any, on B cell cytokine-response profiles 
are largely unknown (113–115). It is noteworthy that in  vivo 
treatment with natalizumab not only limits trafficking but may 
also modify T cell activation, which may reflect a role for VLA-4 
during T cell interaction with APC, including B cells (113). 
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agent, not only reduces the overall number of circulating B cells 
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COnCLUSiOn
The success of anti-CD20 therapy in MS establishes that B cells 
contribute to relapsing disease activity. Though unwelcome, the 
observation that treatment with atacicept (Table 1) exacerbates 
MS, serves to reinforce the concept that targeting B cells can 
change the face of CNS disease activity, while also underscor-
ing the importance of elucidating the functional heterogeneity 
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influence new MS disease activity, potentially through aber-
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play additional roles in propagating disease activity within the 
CNS (see Michel et al., in this issue). Success of B cell targeting 
therapies may lie in restoring and maintaining a favorable balance 
between pro- and anti-inflammatory B cell activities in patients.
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